Open AccessLiraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology Appraisal 664
Author(s) -
Hassan Kahal,
Kamrudeen Mohammed,
Kathryn Lonnen,
Thozhukat Sathyapalan,
Chris Walton
Publication year - 2021
Publication title -
the british journal of diabetes
Language(s) - English
Resource type - Journals
eISSN - 2397-6241
pISSN - 2397-6233
DOI - 10.15277/bjd.2021.298
Subject(s) - liraglutide , nice , overweight , medicine , obesity , glucagon like peptide 1 , gerontology , family medicine , endocrinology , diabetes mellitus , type 2 diabetes , computer science , programming language
Saxenda, Liraglutide 3.0 mg, is a glucagon-like peptide-1 (GLP-1) analogue that is licensed for the treatment of adults with overweight and obesity. In this commentary we review the NICE technology appraisal (TA664) on the use of Saxenda in the National Health Service (NHS) and its implication in clinical practice.